CurrentCapital BluecrossPolicy MP 2.257

Genetic Testing for Duchenne and Becker Muscular Dystrophy

This policy governs medical necessity and coverage for genetic testing of DMD gene variants to diagnose Duchenne and Becker muscular dystrophies, identify carriers, and guide surveillance/treatment. It applies to Capital BlueCross products (with product variations noted) and affects clinicians ordering genetic testing and members undergoing testing.

Policy Summary

PayerCapital Bluecross

PolicyGenetic Testing for Duchenne and Becker Muscular Dystrophy

Policy CodePolicy MP 2.257

Change TypeNo material change

Effective DateSep 1, 2024

Next Review DateN/A

Key ActionVerify member benefits and preauthorization requirements with Capital BlueCross before ordering genetic testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4.8/100kDMD prevalence

1.6/100kBMD prevalence

1/3De novo proportion

2.5%-7.8%Female carrier rate

High

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Clinical sensitivity

CLIA-highCLIA requirement

Coverage and Medical Necessity Criteria

Medically necessary indications

Genetic testing for DMD gene variants is considered medically necessary in the following distinct situations:

Diagnostic testing in symptomatic males: In an individual assigned male at birth with signs and symptoms of a dystrophinopathy to confirm the diagnosis and direct treatment.

[[chunk 0]]

Testing to guide cardiac surveillance: To confirm or exclude the need for cardiac surveillance.

[[chunk 0]]

Testing for at-risk relatives AFB: For at-risk relatives assigned female at birth to identify heterozygous carriers who are at increased risk for cardiomyopathy and who require routine cardiac surveillance.

[[chunk 0],[chunk 1]]

Testing for at-risk offspring AMB: For at-risk offspring assigned male at birth who are asymptomatic to determine affected status, need for increased medical and cardiac surveillance, and to guide management.

[[chunk 0],[chunk 1]]

Preconception testing: For preconception testing to determine the likelihood of an affected offspring in an individual considering pregnancy.

[[chunk 0]]

Molecular confirmation prior to variant-specific therapy: Molecular genetic confirmation of a pathogenic DMD variant to establish eligibility for exon-skipping and other variant-directed therapies.

[[chunk 17],[chunk 19]]

Supported indications

Covered when testing provides diagnostic confirmation or targeted familial testing

Index male with signs of dystrophinopathy: Genetic testing of the DMD gene to confirm diagnosis without muscle biopsy is supported because virtually all males with DMD/BMD have identifiable DMD variants and testing can establish diagnosis and guide treatment.

[[chunk 22]]

Female relative testing for known familial variant: Targeted DMD testing for a known familial variant to determine carrier status is supported due to expected high clinical validity and implications for cardiac surveillance and reproductive planning.

[[chunk 22]]

Asymptomatic male offspring/sibling of carrier or affected patient: Targeted testing for a known familial variant is supported because detection necessitates or eliminates the need for increased medical and cardiac surveillance.

[[chunk 23]]

Genetic testing for DMD gene variants is considered investigational/insufficient evidence for general use when the indication is not one of the specific medically necessary situations listed in this policy. The policy specifies distinct covered uses (diagnostic testing in symptomatic males; testing to guide cardiac surveillance; testing of at‑risk relatives assigned female at birth [AFB] to identify carriers; testing of at‑risk male offspring assigned male at birth [AMB]; preconception testing; and molecular confirmation prior to variant‑directed therapies). Outside of those listed indications, there is insufficient evidence to support benefit and testing is classified as investigational.

The presence of this medical policy does not guarantee that a specific test or service is a covered benefit under a member’s health benefit plan. Benefit determinations (including exclusions, limits, and preauthorization requirements) are governed by the member’s applicable plan language. Providers and members should consult the member’s health benefit plan or contact Capital Blue Cross for benefit and preauthorization information.

Any indication that is not included in the policy’s enumerated medically necessary list is considered investigational and not supported by sufficient evidence for coverage under this policy. Requests for testing for indications outside the listed medically necessary criteria may be denied on the basis of investigational status.

Specific Indications Considered Medically Necessary

Diagnostic testing in symptomatic males to confirm dystrophinopathy and guide treatment.

Clinical presentation requiring diagnostic testing: Male with clinical signs or symptoms suggestive of dystrophinopathy (e.g., delayed motor milestones, progressive weakness) where genetic testing will confirm diagnosis and direct treatment.

See Summary of Evidence supporting high clinical sensitivity for males with DMD/BMD [[chunk 22]]

Diagnostic testing modality: Molecular genetic testing of the DMD gene capable of detecting deletions, duplications, and sequence variants; testing can usually establish diagnosis without muscle biopsy.

[[chunk 17]]

Purpose of testing: To establish genetic diagnosis to initiate appropriate management and to distinguish between Duchenne and Becker muscular dystrophy.

[[chunk 22]]

Procedure and Diagnosis Codes

Covered when medically necessary (example procedure codes)CPTCovered

81161	Use when there is a known familial variant; not otherwise specified
81403	Procedure code listed (coverage unspecified in text)
81408	Procedure code listed (coverage unspecified in text)
0218U	Procedure code listed (coverage unspecified in text)

Diagnosis and family-history codesICD-10

G71.01	Duchenne_or Becker muscular dystrophy
R62.59	Other lack of expected normal physiological development in childhood
Z31.430	Encounter of female for testing for genetic disease carrier status for procreative management
Z84.81	Family history of carrier of genetic disease
284.89	Family history of other specified conditions

inv-08: Serum creatine kinase (CK) elevation — typical range and clinical note

Typical CK elevationUsually at least 10–20 times the upper limit of normal (approximately 5,000 to 150,000 IU/L)

Clinical contextElevation is nonspecific but is consistently present in affected patients and commonly prompts further neuromuscular evaluation

Triggering findingsMay be detected incidentally during testing for unrelated indications (eg, transaminase elevation) or after observation of abnormal muscle function in a male child

Member and Test Eligibility Details

For the purposes of familial and targeted testing, individuals assigned female at birth (AFB) who are considered at‑risk include first‑ and second‑degree relatives of a proband with a DMD‑associated dystrophinopathy. Examples include the proband’s mother, sisters or siblings AFB, offspring AFB, maternal grandmother, maternal aunts, and their offspring. Identifying heterozygous carriers among at‑risk AFB individuals informs need for routine cardiac surveillance and reproductive planning.

The policy defines an at‑risk AFB as a female‑assigned relative who has a family relationship to a person with a DMD‑associated variant (see examples above). Testing in these at‑risk AFB individuals is intended to determine carrier status, which has implications for cardiac surveillance and for assessing the likelihood of affected offspring.

Additional eligibility considerations include availability of a known familial variant and appropriate documentation. Targeted testing is supported when a familial DMD variant is known; coding examples in the policy (e.g., procedure codes when a familial variant is known and family‑history diagnosis codes such as Z84.81) illustrate scenarios where targeted familial testing is appropriate and clinically indicated.

Molecular genetic testing of the DMD gene can usually establish the diagnosis in symptomatic males without the need for a muscle biopsy. Muscle biopsy is generally reserved for cases where deletion/duplication testing and sequencing fail to identify a pathogenic variant or when pathology is otherwise required to resolve diagnostic uncertainty.

Testing methods should include assays capable of detecting the full spectrum of DMD variants (deletions, duplications, and sequence variants) and adhere to accepted reporting standards (HGVS nomenclature and ACMG‑AMP variant classification). Molecular confirmation is also required to determine eligibility for variant‑directed therapies such as exon‑skipping agents, which target specific exon‑amenable mutations.

Provider Responsibilities and Operational Notes

Prior Authorization

Product-specific prior authorization / benefit variation

This policy applies only to certain Capital Blue Cross programs and products. Benefit variations may exist across products (including FEP PPO and others). Confirm the member’s specific health benefit plan for coverage details; the presence of this policy does not guarantee that testing is a covered benefit under the member’s plan.

Applicable products may have specific prior authorization or coverage rules.
FEP PPO: refer to FEP Medical Policy Manual

Prior Authorization

Preauthorization based on member plan

Verify the member’s health benefit plan for preauthorization requirements before ordering testing. Some plans require prior authorization; services may be subject to plan limits, exclusions, or different administrative processes.

Contact Capital Blue Cross or review the member’s benefit plan to confirm preauthorization and coverage requirements.
Medical policy presence does not replace plan-level preauthorization procedures.

Investigational and Non-Covered Uses

Genetic testing for DMD gene variants for indications other than those specifically listed as medically necessary in this policy is considered investigational and is not covered under the policy. Requests for testing for other indications may be denied due to insufficient evidence of clinical benefit.

The existence of this medical policy does not imply that the service is a covered benefit under every member’s plan. Coverage is determined by the member’s specific health benefit plan; items not covered by that plan remain excluded regardless of this policy. Providers should verify coverage and authorization requirements with the member’s plan.

Background and Clinical Context

Variants in the DMD gene are the cause of a spectrum of X‑linked dystrophinopathies, including Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and DMD‑associated dilated cardiomyopathy. Genetic testing can confirm diagnosis, distinguish DMD from BMD, identify female heterozygous carriers at risk for cardiomyopathy, and guide surveillance and variant‑specific therapies.

Definitions and Terminology

inv-18: Variant nomenclature and classification — ACMG-AMP terms and HGVS nomenclature

Recommended classification termsUse ACMG-AMP standard terms: pathogenic; likely pathogenic; variant of uncertain significance; likely benign; benign

Nomenclature standardReport variants using HGVS (Human Genome Variation Society) nomenclature as the international standard for DNA variant reporting

PurposeStandards apply to clinical laboratory genetic tests including single genes, panels, exomes, and genomes to support consistent interpretation

inv-19: At-risk AFB definition — who qualifies as at-risk assigned female at birth relatives

Who qualifies (AFB)At-risk individuals assigned female at birth (AFB) are first- and second-degree relatives: the proband's mother; proband's siblings who are AFB; proband's offspring who are AFB; the proband's maternal grandmother; maternal aunts and their offspring

Policy Changes and Effective Dates

2024-09-01policy_effective_dateLatest

Policy MP 2.257 became effective on 2024-09-01 (document lists Effective Date: 9/1/2024).

2024-05-28last_review

Policy record indicates a last review date of 2024-05-28.

benefit_variation_note

Policy Summary

PayerCapital Bluecross

PolicyGenetic Testing for Duchenne and Becker Muscular Dystrophy

Policy CodePolicy MP 2.257

Change TypeNo material change

Effective DateSep 1, 2024

Next Review DateN/A

Key ActionVerify member benefits and preauthorization requirements with Capital BlueCross before ordering genetic testing.

SourceLink

On This Page

Testing of at-risk female relatives (AFB) to identify carriers and guide cardiac surveillance.

Eligible individuals AFB: At-risk female relatives (AFB) as defined in Policy Guidelines (first- and second-degree relatives including proband's mother, siblings AFB, offspring AFB, maternal grandmother, maternal aunts, and their offspring).

[[chunk 1]]

Indication for testing: Targeted or comprehensive DMD gene testing to determine heterozygous carrier status in order to guide routine cardiac surveillance and reproductive planning.

Clinical utility inferred from chain of evidence; carrier status impacts surveillance [[chunk 22]]

Counseling: Genetic counseling is recommended to discuss implications for cardiac surveillance and reproductive options prior to testing.

[[chunk 5]]

Testing of at-risk male offspring (AMB), including asymptomatic offspring, to determine affected status and need for surveillance.

Eligible individuals AMB: At-risk male offspring assigned male at birth (AMB) defined as asymptomatic male offspring of a female DMD familial variant carrier or male sibling of an affected patient.

[[chunk 1],[chunk 23]]

Indication for testing: Targeted testing for a known familial DMD variant or comprehensive DMD testing when familial variant is unknown to determine affected status and need for increased medical and cardiac surveillance.

Detection necessitates or eliminates need for increased surveillance [[chunk 23]]

Clinical impact: Positive results guide initiation of surveillance and management; negative results may obviate increased surveillance.

[[chunk 23]]

Preconception testing to determine likelihood of affected offspring.

Preconception testing indication: Testing of individuals considering pregnancy (including prospective mothers and partners) to determine the likelihood of having an affected offspring.

[[chunk 0]]

Use of results: Results used for reproductive counseling, risk estimation, and consideration of reproductive options.

At-risk definitions per Policy Guidelines [[chunk 1]]

Molecular confirmation to determine eligibility for exon-skipping and other variant-specific therapies (eteplirsen, golodirsen, viltolarsen, casimersen).

Molecular confirmation for therapy eligibility: Molecular genetic confirmation of a pathogenic DMD variant is required to establish eligibility for exon-skipping and other variant-directed therapies (e.g., eteplirsen for exon 51; golodirsen or viltolarsen for exon 53; casimersen for exon 45).

[[chunk 19],[chunk 17]]

Assay requirements: Testing must identify the specific pathogenic variant and exon amenability to determine suitability for exon-skipping agents or other variant-specific treatments.

[[chunk 19]]

Diagnostic DMD gene testing in males with signs/symptoms to confirm diagnosis without muscle biopsy.

Replace muscle biopsy: Genetic testing of the DMD gene is supported to confirm diagnosis in males with signs/symptoms of dystrophinopathy without the need for muscle biopsy in most cases.

Molecular testing can establish diagnosis without muscle biopsy in most patients [[chunk 17],[chunk 22]]

High clinical sensitivity: Virtually all males with DMD/BMD have identifiable DMD variants, providing high clinical sensitivity for molecular testing.

[[chunk 22]]

Targeted DMD testing for known familial variant in female relatives to determine carrier status.

Targeted testing when familial variant known: Targeted DMD testing for a known familial variant in female relatives to determine carrier status and inform cardiac surveillance and reproductive planning.

Expected high clinical validity though direct evidence limited [[chunk 22]]

Documentation of the known familial variant (e.g., previous testing report) and family history is recommended to support targeted testing.

Family-history definitions per Policy Guidelines [[chunk 1]]

Targeted DMD testing for asymptomatic male offspring or male siblings of known carriers/affected patients.

Targeted testing for asymptomatic male offspring/siblings: Targeted testing for a known familial DMD variant in asymptomatic male offspring or male siblings of known carriers/affected patients to determine affected status.

Detection impacts surveillance and management; use familial-variant procedure code when applicable (e.g., 81161) [[chunk 23],[chunk 29]]

Clinical action based on result: A positive result establishes need for increased medical and cardiac surveillance; a negative result may obviate need for increased surveillance.

[[chunk 23]]

Documentation Required

Testing precedes variant-directed therapy

Obtain molecular genetic testing and confirmation of the DMD pathogenic variant prior to initiating variant-directed therapies (for example, exon-skipping agents indicated for specific exon-amenable mutations). Documentation of the specific confirmed variant is required to support use of exon-skipping or other mutation-directed treatments.

Therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53), viltolarsen (Viltepso), and casimersen (Amondys 45) are indicated only for patients with a confirmed dystrophin variant amenable to the specific exon skip.
Order and result documentation should clearly identify the confirmed mutation to justify variant-directed therapy.

Documentation Required

Genetic counseling documentation

Formal genetic counseling is recommended and should be provided and documented for patients undergoing testing or at risk for inherited dystrophinopathies. Counseling should be performed by personnel with experience in genetic medicine and testing methods to ensure appropriate interpretation and informed decision-making.

Document that genetic counseling occurred and include counseling notes in the medical record.
Genetic counseling may alter testing utilization and help prevent inappropriate testing.

Clinical implication

Heterozygous AFB carriers are at increased risk for cardiomyopathy and require routine cardiac surveillance

Use caseTargeted testing of AFB relatives is indicated to identify carriers for surveillance and reproductive planning

inv-20: At-risk AMB definition — definition for at-risk assigned male at birth offspring

Who qualifies (AMB)At-risk assigned male at birth (AMB) offspring are defined as asymptomatic male offspring of an individual with dystrophinopathy

Purpose of testingTargeted testing of at-risk AMB identifies affected males who need increased medical and cardiac surveillance

Clinical noteDetection in asymptomatic AMB offspring impacts surveillance and management even in absence of symptoms

inv-21: Exon-skipping — definition and therapeutic concept

DefinitionExon-skipping is a molecular therapy using antisense oligonucleotides to skip transcription of a targeted exon and restore a correct reading frame

Therapeutic effectSkipping the mutated exon can produce a dystrophin protein with restored reading frame that may yield milder (Becker-like) phenotypic expression

Approved examplesExon-skipping agents with FDA approval include eteplirsen (Exondys 51), golodirsen (Vyondys 53), viltolarsen (Viltepso), and casimersen (Amondys 45) for specific exon-amenable DMD variants

inv-22: Gene therapy (Elevidys) — approved gene therapy description and eligibility note

Product name and active agentDelandistrogene moxeparvovec-rokl (brand name: Elevidys)

Approved useFDA-approved for ambulatory children 4 to 5 years of age with Duchenne muscular dystrophy and a confirmed DMD mutation

Eligibility noteMolecular confirmation of a DMD gene mutation is required to establish eligibility for this gene therapy

Policy clarifies that existence of this medical policy does not guarantee coverage under a member's specific health benefit plan (benefit variations noted).